In the 12-week, placebo-controlled, clinical trial, akathisia was the most common adverse reaction with an incidence ≥5% and at least twice the rate of placebo in patients treated with ARISTADA1
- 2 out of 415 patients discontinued ARISTADA® (aripiprazole lauroxil) due to akathisia, which was not dose-related2
- Benzodiazepines and short-acting beta-blockers were permitted for treatment-emergent akathisia as needed2
References: 1. ARISTADA [package insert]. Waltham, MA: Alkermes, Inc; 2018. 2. Data on file. Alkermes, Inc.